uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.710 | Q17 | What gene does the drug Cinnarizine target? | The drug Cinnarizine targets 5 genes: CACNA1C, CACNA1F, CACNA1S, HRH1 and CACNA1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cinnarizine%" OR LOWER(tradeNames_string) LIKE "%cinnarizine%" OR LOWER(drugSynonyms_string) LIKE "%cinnarizine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4535', 'drugName': 'Cinnarizine', 'tradeNames_string': 'Marzine r.f., Mylan travel sickness, Stugeron, Stugeron fte', 'drugSynonyms_string': '516 MD, 516-MD, Aplactan, Aplexal, Artate, Carecin, Cerebolan, Cerepar, Cinaperazine, Cinarizine, Cinazyn, Cinnacet, Cinnageron, Cinnarizine, Cinnipirine, Corathiem, Denapol, Dimitron, Eglen, Folcodal, Giganten, Glanil, Hilactan, Ixertol, Katoseran, Labyrin, Midronal, Mitronal, NSC-758400, Olamin, Processine, R 1575, R 516, R-1575, R-516, Sedatromin, Sepan, Siptazin, Spaderizine, Stugeron, Stunarone, Stutgeron, Stutgin', 'linkedDiseasesDrug_string': 'Vertigo (HP_0002321)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4536', 'drugName': 'Cinnarizine', 'tradeNames_string': 'Marzine r.f., Mylan travel sickness, Stugeron, Stugeron fte', 'drugSynonyms_string': '516 MD, 516-MD, Aplactan, Aplexal, Artate, Carecin, Cerebolan, Cerepar, Cinaperazine, Cinarizine, Cinazyn, Cinnacet, Cinnageron, Cinnarizine, Cinnipirine, Corathiem, Denapol, Dimitron, Eglen, Folcodal, Giganten, Glanil, Hilactan, Ixertol, Katoseran, Labyrin, Midronal, Mitronal, NSC-758400, Olamin, Processine, R 1575, R 516, R-1575, R-516, Sedatromin, Sepan, Siptazin, Spaderizine, Stugeron, Stunarone, Stutgeron, Stutgin', 'linkedDiseasesDrug_string': 'Vertigo (HP_0002321)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1222 | Q17 | What gene does the drug Pelacarsen target? | The drug Pelacarsen is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene LPA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pelacarsen%" OR LOWER(tradeNames_string) LIKE "%pelacarsen%" OR LOWER(drugSynonyms_string) LIKE "%pelacarsen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5695', 'drugName': 'Pelacarsen', 'tradeNames_string': '', 'drugSynonyms_string': 'AKCEA-APO(a)-LRx, ISIS 681257, ISIS-681257 FREE ACID, Ionis-apo(a)-lrx, Pelacarsen', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Hyperlipoproteinemia (MONDO_0037748), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'LPA (ENSG00000198670)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1308 | Q17 | What gene does the drug Sertraline target? | The drug Sertraline targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sertraline%" OR LOWER(tradeNames_string) LIKE "%sertraline%" OR LOWER(drugSynonyms_string) LIKE "%sertraline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_464', 'drugName': 'Sertraline Hydrochloride', 'tradeNames_string': 'Aremis, Besitron, Lustral, Sertraline hydrochloride, Zoloft', 'drugSynonyms_string': 'CP-51,974-1, CP-51974-1, NSC-746308, NSC-758948, Sertraline (as hydrochloride), Sertraline hcl, Sertraline hydrochloride', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Unipolar Depression (EFO_0003761), Headache (HP_0002315), Obsessive-Compulsive Disorder (EFO_0004242), Huntington Disease (MONDO_0007739), Panic Disorder (EFO_0004262), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Intellectual Disability (HP_0001249)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_514', 'drugName': 'Sertraline', 'tradeNames_string': '', 'drugSynonyms_string': 'Sertraline', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cryptococcal Meningitis (EFO_0007228), Obesity (EFO_0001073), Panic Disorder (EFO_0004262), Myelodysplastic Syndrome (EFO_0000198), Intellectual Disability (HP_0001249), Hepatitis C Virus Infection (EFO_0003047), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Postpartum Depression (EFO_0007453), Headache (HP_0002315), Mood Disorder (EFO_0004247), Fragile X Syndrome (MONDO_0010383), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Coccidioidomycosis (EFO_0007211), Autism Spectrum Disorder (EFO_0003756), Pruritus (HP_0000989), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Generalized Anxiety Disorder (EFO_1001892), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2675', 'drugName': 'Dasotraline', 'tradeNames_string': '', 'drugSynonyms_string': '(1r,4s)-trans-norsertraline, Dasotraline, Norsertraline, (1r,4s)-trans-, SEP-225289', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Major Depressive Disorder (MONDO_0002009), Eating Disorder (EFO_0005203)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1666 | Q17 | What gene does the drug Amiloride target? | The drug Amiloride targets 3 genes: SCNN1B, SCNN1A and SCNN1G. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amiloride%" OR LOWER(tradeNames_string) LIKE "%amiloride%" OR LOWER(drugSynonyms_string) LIKE "%amiloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2590', 'drugName': 'Amiloride Hydrochloride', 'tradeNames_string': 'Amilamont, Amiloride hydrochloride, Amilospare 5, Amoride, Berkamil, Midamor', 'drugSynonyms_string': 'Amiloride hcl, Amiloride hydrochloride, Amiloride hydrochloride anhydrous, Amiloride hydrochloride dehydrate, Amiloride hydrochloride dihydrate, Amiloridi hydrochloridum, Amipramidine, Anhydrous amiloride hydrochloride, NSC-755847', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Congestive Heart Failure (EFO_0000373), Cystic Fibrosis (MONDO_0009061), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCNN1A (ENSG00000111319), SCNN1B (ENSG00000168447), SCNN1G (ENSG00000166828)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3975', 'drugName': 'Amiloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Amiclaran, Amiloride, Hydro-Ride, Midamor', 'linkedDiseasesDrug_string': 'Optic Neuritis (EFO_0007405), Congestive Heart Failure (EFO_0000373), Coronary Artery Disease (EFO_0001645), Migraine With Aura (MONDO_0005475), Primary Hyperparathyroidism (EFO_0008519), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cardiac Arrhythmia (EFO_0004269), Cystic Fibrosis (MONDO_0009061), Peripheral Demyelination (HP_0011096), Secondary Progressive Multiple Sclerosis (EFO_0008522)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCNN1A (ENSG00000111319), SCNN1B (ENSG00000168447), SCNN1G (ENSG00000166828)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1270 | Q17 | What gene does the drug Resiniferatoxin target? | The drug Resiniferatoxin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TRPV1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%resiniferatoxin%" OR LOWER(tradeNames_string) LIKE "%resiniferatoxin%" OR LOWER(drugSynonyms_string) LIKE "%resiniferatoxin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2075', 'drugName': 'Resiniferatoxin', 'tradeNames_string': 'Neuroclastin', 'drugSynonyms_string': 'Lopain, MTX-71, Mtx-071, RTX, Resiniferatoxin', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TRPV1 (ENSG00000196689)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.493 | Q17 | What gene does the drug Barasertib target? | The drug Barasertib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene AURKB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%barasertib%" OR LOWER(tradeNames_string) LIKE "%barasertib%" OR LOWER(drugSynonyms_string) LIKE "%barasertib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3821', 'drugName': 'Barasertib', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD 1152, AZD-1152, AZD1152, Azd-1152, Barasertib, Barasertib (who-dd)', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Lymphoma (EFO_0000574), Myeloid Leukemia (MONDO_0004643), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'AURKB (ENSG00000178999)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.565 | Q17 | What gene does the drug Glafenine target? | The drug Glafenine targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glafenine%" OR LOWER(tradeNames_string) LIKE "%glafenine%" OR LOWER(drugSynonyms_string) LIKE "%glafenine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_579', 'drugName': 'Glafenine', 'tradeNames_string': '', 'drugSynonyms_string': 'Glafenin, Glafenine, Glaphenine, Glycerylaminophenaquine, NSC-757808, R 1707, R-1707', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Fever (HP_0001945)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1151 | Q17 | What gene does the drug Bms-754807 target? | The drug Bms-754807 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IGF1R and INSR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-754807%" OR LOWER(tradeNames_string) LIKE "%bms-754807%" OR LOWER(drugSynonyms_string) LIKE "%bms-754807%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1288', 'drugName': 'Bms-754807', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-754807, BMS754807, Bms 754807, Bms-754807', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1289', 'drugName': 'Bms-754807', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-754807, BMS754807, Bms 754807, Bms-754807', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443), INSR (ENSG00000171105)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1129 | Q17 | What gene does the drug Ranolazine target? | The drug Ranolazine targets 2 genes: SCN5A and SCN4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ranolazine%" OR LOWER(tradeNames_string) LIKE "%ranolazine%" OR LOWER(drugSynonyms_string) LIKE "%ranolazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6340', 'drugName': 'Ranolazine', 'tradeNames_string': 'Aspruzyo sprinkle, Ranexa, Ranolazine', 'drugSynonyms_string': 'Aspruzyo, CVT-303, NSC-759100, RS-43285-003, Ran d, Ranolazine', 'linkedDiseasesDrug_string': "Prolonged Qt Interval (HP_0001657), Diastolic Heart Failure (EFO_1000899), Atrial Fibrillation (EFO_0000275), Crohn'S Disease (EFO_0000384), Angina Pectoris (EFO_0003913), Amyotrophic Lateral Sclerosis (MONDO_0004976), Paramyotonia Congenita Of Von Eulenburg (MONDO_0008195), Dilated Cardiomyopathy (EFO_0000407), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319), Pulmonary Arterial Hypertension (EFO_0001361), Kidney Disease (EFO_0003086), Irritable Bowel Syndrome (EFO_0000555), Vascular Disease (EFO_0004264), Acute Coronary Syndrome (EFO_0005672), Type 2 Diabetes Mellitus (MONDO_0005148), Myocardial Ischemia (EFO_1001375)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN4A (ENSG00000007314), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6341', 'drugName': 'Ranolazine', 'tradeNames_string': 'Aspruzyo sprinkle, Ranexa, Ranolazine', 'drugSynonyms_string': 'Aspruzyo, CVT-303, NSC-759100, RS-43285-003, Ran d, Ranolazine', 'linkedDiseasesDrug_string': "Prolonged Qt Interval (HP_0001657), Diastolic Heart Failure (EFO_1000899), Atrial Fibrillation (EFO_0000275), Crohn'S Disease (EFO_0000384), Angina Pectoris (EFO_0003913), Amyotrophic Lateral Sclerosis (MONDO_0004976), Paramyotonia Congenita Of Von Eulenburg (MONDO_0008195), Dilated Cardiomyopathy (EFO_0000407), Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319), Pulmonary Arterial Hypertension (EFO_0001361), Kidney Disease (EFO_0003086), Irritable Bowel Syndrome (EFO_0000555), Vascular Disease (EFO_0004264), Acute Coronary Syndrome (EFO_0005672), Type 2 Diabetes Mellitus (MONDO_0005148), Myocardial Ischemia (EFO_1001375)", 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN4A (ENSG00000007314), SCN5A (ENSG00000183873)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.808 | Q17 | What gene does the drug Nevanimibe target? | The drug Nevanimibe is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SOAT1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nevanimibe%" OR LOWER(tradeNames_string) LIKE "%nevanimibe%" OR LOWER(drugSynonyms_string) LIKE "%nevanimibe%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3381', 'drugName': 'Nevanimibe', 'tradeNames_string': '', 'drugSynonyms_string': 'Nevanimibe, PD 132301, PD-132301', 'linkedDiseasesDrug_string': 'Cushing Syndrome (EFO_0003099), Congenital Adrenal Hyperplasia (MONDO_0018479), Adrenal Cortex Carcinoma (EFO_1000796)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SOAT1 (ENSG00000057252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.518 | Q17 | What gene does the drug Ziprasidone target? | The drug Ziprasidone targets 3 genes: HTR2C, HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ziprasidone%" OR LOWER(tradeNames_string) LIKE "%ziprasidone%" OR LOWER(drugSynonyms_string) LIKE "%ziprasidone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1685', 'drugName': 'Ziprasidone', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-88059, Geodon, Zipradon, Ziprasidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Ventricular Tachycardia (EFO_0005306), Drug Dependence (EFO_0003890), Borderline Personality Disorder (HP_0012076), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4288', 'drugName': 'Ziprasidone Mesylate', 'tradeNames_string': 'Geodon', 'drugSynonyms_string': 'CP-88, 059-27, CP-88,059-27, CP-88059-27, CP-8805927, NSC-760351, Ziprasidone mesilate, Ziprasidone mesilate trihydrate, Ziprasidone mesylate, Ziprasidone mesylate anhydrous', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4287', 'drugName': 'Ziprasidone Mesylate', 'tradeNames_string': 'Geodon', 'drugSynonyms_string': 'CP-88, 059-27, CP-88,059-27, CP-88059-27, CP-8805927, NSC-760351, Ziprasidone mesilate, Ziprasidone mesilate trihydrate, Ziprasidone mesylate, Ziprasidone mesylate anhydrous', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1683', 'drugName': 'Ziprasidone', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-88059, Geodon, Zipradon, Ziprasidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Ventricular Tachycardia (EFO_0005306), Drug Dependence (EFO_0003890), Borderline Personality Disorder (HP_0012076), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3392', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3393', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4286', 'drugName': 'Ziprasidone Mesylate', 'tradeNames_string': 'Geodon', 'drugSynonyms_string': 'CP-88, 059-27, CP-88,059-27, CP-88059-27, CP-8805927, NSC-760351, Ziprasidone mesilate, Ziprasidone mesilate trihydrate, Ziprasidone mesylate, Ziprasidone mesylate anhydrous', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1684', 'drugName': 'Ziprasidone', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-88059, Geodon, Zipradon, Ziprasidone', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Cardiovascular Disease (EFO_0000319), Cardiac Arrhythmia (EFO_0004269), Ventricular Tachycardia (EFO_0005306), Drug Dependence (EFO_0003890), Borderline Personality Disorder (HP_0012076), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), HTR2C (ENSG00000147246)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3394', 'drugName': 'Ziprasidone Hydrochloride', 'tradeNames_string': 'Geodon, Zeldox, Ziprasidone hydrochloride', 'drugSynonyms_string': 'CP-88,059-1, CP-88059-1, CP-880591, Ziprasidone hydrochloride, Ziprasidone hydrochloride hydrate, Ziprasidone hydrochloride monohydrate', 'linkedDiseasesDrug_string': 'Ventricular Tachycardia (EFO_0005306), Bipolar I Disorder (EFO_0009963), Agitation (HP_0000713), Cardiac Arrhythmia (EFO_0004269), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.640 | Q17 | What gene does the drug Deserpidine target? | The drug Deserpidine targets the gene SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%deserpidine%" OR LOWER(tradeNames_string) LIKE "%deserpidine%" OR LOWER(drugSynonyms_string) LIKE "%deserpidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4303', 'drugName': 'Deserpidine', 'tradeNames_string': 'Harmonyl', 'drugSynonyms_string': 'Deserpidine, Deserpidine, (-)-, Halmonyl, NSC-72138, Recanescin', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1480 | Q17 | What gene does the drug Maprotiline target? | The drug Maprotiline targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%maprotiline%" OR LOWER(tradeNames_string) LIKE "%maprotiline%" OR LOWER(drugSynonyms_string) LIKE "%maprotiline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_191', 'drugName': 'Maprotiline', 'tradeNames_string': '', 'drugSynonyms_string': 'BA-34,276 FREE BASE, BA-34,276 [AS HYDROCHLORIDE], BA-34276 FREE BASE, Maprotiline', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Dementia (HP_0000726), Anxiety (EFO_0005230), Brain Neoplasm (EFO_0003833), Depressive Disorder (MONDO_0002050), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4631', 'drugName': 'Maprotiline Hydrochloride', 'tradeNames_string': 'Ludiomil, Maprotiline hydrochloride', 'drugSynonyms_string': 'BA-34,276, BA-34276, Maprotiline hcl, Maprotiline hydrochloride, NSC-757085', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 1980, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1789 | Q17 | What gene does the drug Acotiamide Hydrochloride target? | The drug Acotiamide Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acotiamide hydrochloride%" OR LOWER(tradeNames_string) LIKE "%acotiamide hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%acotiamide hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3004', 'drugName': 'Acotiamide Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Acotiamide hydrochloride, Acotiamide hydrochloride hydrate, Acotiamide hydrochloride trihydrate, YM-443, YM443, Z-338', 'linkedDiseasesDrug_string': 'Dyspepsia (EFO_0008533)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1546 | Q17 | What gene does the drug Citalopram Hydrobromide target? | The drug Citalopram Hydrobromide targets the gene SLC6A4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%citalopram hydrobromide%" OR LOWER(tradeNames_string) LIKE "%citalopram hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%citalopram hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1197', 'drugName': 'Citalopram Hydrobromide', 'tradeNames_string': 'Celexa, Cipramil, Citalopram hydrobromide, Paxoran', 'drugSynonyms_string': 'Citalopram (as hydrobromide), Citalopram hbr, Citalopram hydrobromide, LU 10-171-B, LU-10-171-B, NSC-758684', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Panic Disorder (EFO_0004262), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1160 | Q17 | What gene does the drug Insulin Zinc Susp Extended Beef target? | The drug Insulin Zinc Susp Extended Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin zinc susp extended beef%" OR LOWER(tradeNames_string) LIKE "%insulin zinc susp extended beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin zinc susp extended beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1883', 'drugName': 'Insulin Zinc Susp Extended Beef', 'tradeNames_string': 'Ultralente insulin', 'drugSynonyms_string': 'Insulin zinc susp extended beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.797 | Q17 | What gene does the drug Prednisolone Acetate target? | The drug Prednisolone Acetate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prednisolone acetate%" OR LOWER(tradeNames_string) LIKE "%prednisolone acetate%" OR LOWER(drugSynonyms_string) LIKE "%prednisolone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5344', 'drugName': 'Prednisolone Acetate', 'tradeNames_string': 'Econopred, Flo-pred, Meticortelone, Omnipred, Pred forte, Pred fte, Pred mild, Prednisolone acetate, Sterane, Ultracortenol', 'drugSynonyms_string': 'NSC-10966, Prednisolone 21-acetate, Prednisolone Acetate, Prednisolone acetate, Prednisoloni acetas', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Anterior Uveitis (EFO_1000811), Uveitis (EFO_1001231), Iritis (EFO_1000997), Retinal Vein Occlusion (EFO_1001157), Sciatica (HP_0011868), Cataract (MONDO_0005129), Multiple Sclerosis (MONDO_0005301), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Corneal Scarring (HP_0000559), Inflammation (MP_0001845), Anemia (MONDO_0002280), Low Back Pain (HP_0003419), Nasal Congestion (HP_0001742), Eye Infection (EFO_1001888), Macular Retinal Edema (MONDO_0003005)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_675', 'drugName': 'Methylprednisolone Acetate', 'tradeNames_string': 'Depmedalone, Depo-medrol, Depo-medrone, M-predrol, Medrol, Medrol acetate, Methylprednisolone acetate, Neo-medrone', 'drugSynonyms_string': 'Methyl prednisolone acetate, Methylprednisolone 21-acetate, Methylprednisolone acetate, NSC-48985', 'linkedDiseasesDrug_string': 'Lateral Epicondylitis (EFO_1001896), Pain (EFO_0003843), Nephrotic Syndrome (EFO_0004255), Uveitis (EFO_1001231), Neuropathic Pain (EFO_0005762), Frozen Shoulder (EFO_1000941), Lymphoma (EFO_0000574), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Fungal Infectious Disease (MONDO_0002041), Brain Neoplasm (EFO_0003833), Anemia (MONDO_0002280), Rheumatoid Arthritis (EFO_0000685), Gout (EFO_0004274), Osteoarthritis (MONDO_0005178), Leukemia (EFO_0000565), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Shoulder Impingement Syndrome (EFO_1001178), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.119 | Q17 | What gene does the drug Flurazepam Hydrochloride target? | The drug Flurazepam Hydrochloride targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flurazepam hydrochloride%" OR LOWER(tradeNames_string) LIKE "%flurazepam hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%flurazepam hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_653', 'drugName': 'Flurazepam Hydrochloride', 'tradeNames_string': 'Dalmane, Flurazepam hydrochloride', 'drugSynonyms_string': 'Flurazepam, Flurazepam dihydrochloride, Flurazepam hydrochloride, Flurazepam hydrochloride civ, NSC-78559, RO 5-6901, RO-5-6901', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.747 | Q17 | What gene does the drug Fibrinolysin, Human target? | The drug Fibrinolysin, Human targets 3 genes: FGA, FGB and FGG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fibrinolysin, human%" OR LOWER(tradeNames_string) LIKE "%fibrinolysin, human%" OR LOWER(drugSynonyms_string) LIKE "%fibrinolysin, human%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1199', 'drugName': 'Fibrinolysin, Human', 'tradeNames_string': 'Actase', 'drugSynonyms_string': 'Fibrinolysin, Fibrinolysin (human), Fibrinolysin human, Fibrinolysin, human, Plasmin, Plasmin (bos taurus), Plasmin (bovine), Plasmin (human), Plasmin bovine, Thrombolysin.', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Ischemic Stroke (HP_0002140)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FGA (ENSG00000171560), FGB (ENSG00000171564), FGG (ENSG00000171557)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1691 | Q17 | What gene does the drug Su-9516 target? | The drug Su-9516 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CDK2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%su-9516%" OR LOWER(tradeNames_string) LIKE "%su-9516%" OR LOWER(drugSynonyms_string) LIKE "%su-9516%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2384', 'drugName': 'Su-9516', 'tradeNames_string': '', 'drugSynonyms_string': 'SU-9516, Su-9516, Su9516', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CDK2 (ENSG00000123374)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1090 | Q17 | What gene does the drug Tenapanor target? | The drug Tenapanor targets the gene SLC9A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tenapanor%" OR LOWER(tradeNames_string) LIKE "%tenapanor%" OR LOWER(drugSynonyms_string) LIKE "%tenapanor%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4791', 'drugName': 'Tenapanor', 'tradeNames_string': '', 'drugSynonyms_string': 'AZD-1722, KHK-7791, Khk7791, Tenapanor', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Hyperphosphatemia (HP_0002905), Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203), Constipation (HP_0002019)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC9A3 (ENSG00000066230)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3816', 'drugName': 'Tenapanor Hydrochloride', 'tradeNames_string': 'Ibsrela', 'drugSynonyms_string': 'AZD-1722 HYDROCHLORIDE, AZD1722, AZD1722 hydrochloride, RDX-5791, RDX5791, Tenapanor dihydrochloride, Tenapanor hydrochloride', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203), Chronic Kidney Disease (EFO_0003884), Hyperphosphatemia (HP_0002905)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC9A3 (ENSG00000066230)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.837 | Q17 | What gene does the drug Dyclonine Hydrochloride target? | The drug Dyclonine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dyclonine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%dyclonine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%dyclonine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5439', 'drugName': 'Dyclonine Hydrochloride', 'tradeNames_string': 'Dyclone', 'drugSynonyms_string': 'Dyclocaine, Dyclonine HCl, Dyclonine hcl, Dyclonine hydrochloride, NSC-23018', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.122 | Q17 | What gene does the drug Rescinnamine target? | The drug Rescinnamine targets the gene SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rescinnamine%" OR LOWER(tradeNames_string) LIKE "%rescinnamine%" OR LOWER(drugSynonyms_string) LIKE "%rescinnamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4945', 'drugName': 'Rescinnamine', 'tradeNames_string': 'Cinnasil, Moderil', 'drugSynonyms_string': 'Apoterin s, Cartric, Cinnaloid, NSC-15628, Rescinnamine, Rescisan, Resealoid, Reserpinine, Scinnamina, Tsuruselpi s', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.663 | Q17 | What gene does the drug Zimeldine Hydrochloride target? | The drug Zimeldine Hydrochloride targets 17 genes: HTR1F, HTR1D, HTR3D, HTR3C, HTR5A, HTR2A, HTR2B, HTR3E, HTR1B, HTR1E, HTR1A, HTR3B, HTR2C, HTR7, HTR4, HTR3A and HTR6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zimeldine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%zimeldine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%zimeldine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6383', 'drugName': 'Zimeldine Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'H 102/09 HYDROCHLORIDE, Zimeldine hcl, Zimeldine hydrochloride, Zimelidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 17}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1908 | Q17 | What gene does the drug Lomitapide target? | The drug Lomitapide targets 2 genes: P4HB and MTTP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lomitapide%" OR LOWER(tradeNames_string) LIKE "%lomitapide%" OR LOWER(drugSynonyms_string) LIKE "%lomitapide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3058', 'drugName': 'Lomitapide Mesylate', 'tradeNames_string': 'Juxtapid', 'drugSynonyms_string': 'AEGR-733, AEGR-733 MESYLATE, Aegr-733 mesilate, BMS-201038, BMS-201038-04, Lomitapide mesilate, Lomitapide mesylate', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Homozygous Familial Hypercholesterolemia (MONDO_0018328), Familial Hypercholesterolemia (EFO_0004911), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTTP (ENSG00000138823), P4HB (ENSG00000185624)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_476', 'drugName': 'Lomitapide', 'tradeNames_string': 'Lojuxta', 'drugSynonyms_string': 'AEGR-733, BMS-201038, BMS-201038-01, Lomitapide', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Familial Hypercholesterolemia (EFO_0004911), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Homozygous Familial Hypercholesterolemia (MONDO_0018328)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MTTP (ENSG00000138823), P4HB (ENSG00000185624)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.642 | Q17 | What gene does the drug Butabarbital Sodium target? | The drug Butabarbital Sodium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%butabarbital sodium%" OR LOWER(tradeNames_string) LIKE "%butabarbital sodium%" OR LOWER(drugSynonyms_string) LIKE "%butabarbital sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3050', 'drugName': 'Butabarbital Sodium', 'tradeNames_string': 'Butabarb, Butabarbital, Butabarbital sodium, Butalan, Buticaps, Butisol sodium, Sarisol, Sarisol no. 1, Sarisol no. 2, Sodium butabarbital', 'drugSynonyms_string': 'Astrudion, Butabarbital sodium, Butabarbital sodium salt, Loubarb, Mebutal, NSC-11778, Secbutabarbital sodium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.374 | Q17 | What gene does the drug Avl-3288 target? | The drug Avl-3288 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CHRNA7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%avl-3288%" OR LOWER(tradeNames_string) LIKE "%avl-3288%" OR LOWER(drugSynonyms_string) LIKE "%avl-3288%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2542', 'drugName': 'Avl-3288', 'tradeNames_string': '', 'drugSynonyms_string': 'Anvylic-3288, Avl-3288, CCMI, UCI-4083, XY-4083', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Schizoaffective Disorder (EFO_0005411)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.271 | Q17 | What gene does the drug Amphetamine target? | The drug Amphetamine targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amphetamine%" OR LOWER(tradeNames_string) LIKE "%amphetamine%" OR LOWER(drugSynonyms_string) LIKE "%amphetamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4236', 'drugName': 'Amphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1112', 'drugName': 'Methamphetamine', 'tradeNames_string': '', 'drugSynonyms_string': '(s)-phenylmethylaminopropane, J6.362B, Metamfetamine, Methamphetamine, NSC-25115', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Methamphetamine Dependence (EFO_0004701)', 'yearOfFirstApproval': 1943, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5075', 'drugName': 'Dextroamphetamine', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugSynonyms_string': 'Amfetamine, (s)-, Amphetamine, d-, D-amphetamine, Dexamfetamine, Dexampex, Dexamphetamine, Dexedrine, Dexidrine, Dextroamphetamine, Dextroamphetamine resin complex, Dextrostat, Ferndex, NSC-73713, Xelstrym', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5076', 'drugName': 'Dextroamphetamine', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugSynonyms_string': 'Amfetamine, (s)-, Amphetamine, d-, D-amphetamine, Dexamfetamine, Dexampex, Dexamphetamine, Dexedrine, Dexidrine, Dextroamphetamine, Dextroamphetamine resin complex, Dextrostat, Ferndex, NSC-73713, Xelstrym', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1031', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1032', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1033', 'drugName': 'Dextroamphetamine Sulfate', 'tradeNames_string': 'Dexampex, Dexedrine, Dextroamphetamine sulfate, Dextrostat, Ferndex', 'drugSynonyms_string': 'Amphetamine sulfate, dextro, D-amphetamine hemisulfate salt, Dexamfetamine sulfate, Dexamphetamine sulfate, Dexamphetamine sulphate, Dextroamphetamine sulfate, Dextroamphetamine sulfate cii, Dextroamphetamine sulphate, NSC-27104', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_984', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_985', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6177', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6178', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2130', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2131', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2132', 'drugName': 'Lisdexamfetamine Dimesylate', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugSynonyms_string': 'Lisdexamfetamine dimesilate, Lisdexamfetamine dimesylate, Lisdexamfetamine dimethanesulfonate, Lisdexamfetamine mesilate, Lisdexamphetamine dimesilate, NRP-104, NRP104, SPD-489, SPD489, Tyvense', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5557', 'drugName': 'Methamphetamine Hydrochloride', 'tradeNames_string': 'Desoxyn, Methampex, Methamphetamine hydrochloride', 'drugSynonyms_string': 'Desoxyephedrine hydrochloride, Metamfetamine hydrochloride, Methamphetamine hcl, Methamphetamine hydrochloride, Methamphetamine hydrochloride cii, Methylamfetamine hydrochloride, NSC-169505', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1943, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3241', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3242', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3243', 'drugName': 'Dextroamphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine adipate, Dextroamphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1918', 'drugName': 'Hydroxyamphetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Dl-4-hydroxyamphetamine, Dl-p-hydroxyamphetamine, Hydroxyamfetamine, Hydroxyamphetamine, NSC-170995, Norveritol, P-hydroxyamphetamine, Phenol, p-(2-aminopropyl)-, Pulsoton, Racemic p-hydroxyamphetamine', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_2950', 'drugName': 'Hydroxyamphetamine Hydrobromide', 'tradeNames_string': 'Paredrine', 'drugSynonyms_string': 'Hydroxyamfetamine hbr, Hydroxyamfetamine hydrobromide, Hydroxyamphetamine hbr, Hydroxyamphetamine hydrobromide, Hyroxyamfetamine hydrobromide, NSC-61065, Oxamphetamine hydrobromide, Phenol, 4-(2-aminopropyl)-, hbr', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_983', 'drugName': 'Dextroamphetamine Saccharate', 'tradeNames_string': '', 'drugSynonyms_string': 'D-amphetamine saccharate, Dexamfetamine hemisaccharate, Dexamfetamine saccharate, Dexamfetaphine saccharate, Dextroamphetamine saccharate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1232', 'drugName': 'Amphetamine Aspartate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amfetamine aspartate, Amphetamine aspartate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4796', 'drugName': 'Amphetamine Sulfate', 'tradeNames_string': 'Amphetamine sulfate, Benzadrine, Evekeo, Evekeo odt', 'drugSynonyms_string': 'Amfetamine sulfate, Amfetamine sulphate, Amphetamine Sulfate, Amphetamine sulfate, Astedin, Benzedrine, Dl-amphetamine sulfate, Dl-amphetamine sulphate, NSC-170999', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1571', 'drugName': 'Amphetamine', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugSynonyms_string': 'Amfetamin, Amfetamine, Amphetamine, Amphetamine resin complex, Amphetamine, dl-, Dyanavel, NSC-27159, Norephedrane', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1570', 'drugName': 'Amphetamine', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugSynonyms_string': 'Amfetamin, Amfetamine, Amphetamine, Amphetamine resin complex, Amphetamine, dl-, Dyanavel, NSC-27159, Norephedrane', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6179', 'drugName': 'Lisdexamfetamine', 'tradeNames_string': '', 'drugSynonyms_string': 'L-lysine-dextroamphetamine, Lisdexamfetamine, Lisdexamphetamine', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Eating Disorder (EFO_0005203), Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Cocaine Dependence (EFO_0002610), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698), Bulimia Nervosa (EFO_0005204), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5077', 'drugName': 'Dextroamphetamine', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugSynonyms_string': 'Amfetamine, (s)-, Amphetamine, d-, D-amphetamine, Dexamfetamine, Dexampex, Dexamphetamine, Dexedrine, Dexidrine, Dextroamphetamine, Dextroamphetamine resin complex, Dextrostat, Ferndex, NSC-73713, Xelstrym', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1231', 'drugName': 'Amphetamine Aspartate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amfetamine aspartate, Amphetamine aspartate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4235', 'drugName': 'Amphetamine Adipate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amphetamine adipate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4795', 'drugName': 'Amphetamine Sulfate', 'tradeNames_string': 'Amphetamine sulfate, Benzadrine, Evekeo, Evekeo odt', 'drugSynonyms_string': 'Amfetamine sulfate, Amfetamine sulphate, Amphetamine Sulfate, Amphetamine sulfate, Astedin, Benzedrine, Dl-amphetamine sulfate, Dl-amphetamine sulphate, NSC-170999', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.662 | Q17 | What gene does the drug Levorphanol target? | The drug Levorphanol targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levorphanol%" OR LOWER(tradeNames_string) LIKE "%levorphanol%" OR LOWER(drugSynonyms_string) LIKE "%levorphanol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4300', 'drugName': 'Levorphanol', 'tradeNames_string': '', 'drugSynonyms_string': 'Aromarone, IDS-NL-007, Levorphan, Levorphanol, RO 1-5431', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5454', 'drugName': 'Levorphanol Tartrate', 'tradeNames_string': 'Dromoran, Levo-dromoran, Levorphanol tartrate', 'drugSynonyms_string': 'Levorphanol tartrate, Levorphanol tartrate anhydrous, Levorphanol tartrate dihydrate, NSC-91012', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.944 | Q17 | What gene does the drug Brodalumab target? | The drug Brodalumab targets the gene IL17RA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brodalumab%" OR LOWER(tradeNames_string) LIKE "%brodalumab%" OR LOWER(drugSynonyms_string) LIKE "%brodalumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_258', 'drugName': 'Brodalumab', 'tradeNames_string': 'Kyntheum, Siliq', 'drugSynonyms_string': 'AMG 827, AMG-827, Brodalumab, KHK-4827, KHK4827', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Asthma (MONDO_0004979), Pustulosis Palmaris Et Plantaris (MONDO_0015597), Crohn'S Disease (EFO_0000384), Systemic Scleroderma (EFO_0000717), Ankylosing Spondylitis (EFO_0003898), Psoriatic Arthritis (EFO_0003778), Rheumatoid Arthritis (EFO_0000685), Hidradenitis Suppurativa (EFO_1000710), Immune System Disease (EFO_0000540), Psoriasis Vulgaris (EFO_1001494)", 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL17RA (ENSG00000177663)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.829 | Q17 | What gene does the drug Iloperidone target? | The drug Iloperidone targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iloperidone%" OR LOWER(tradeNames_string) LIKE "%iloperidone%" OR LOWER(drugSynonyms_string) LIKE "%iloperidone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4312', 'drugName': 'Iloperidone', 'tradeNames_string': 'Fanapt, Iloperidone', 'drugSynonyms_string': 'HP 873, HP-873, Iloperidone', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Bipolar I Disorder (EFO_0009963), Liver Disease (EFO_0001421), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4313', 'drugName': 'Iloperidone', 'tradeNames_string': 'Fanapt, Iloperidone', 'drugSynonyms_string': 'HP 873, HP-873, Iloperidone', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Post-Traumatic Stress Disorder (EFO_0001358), Bipolar I Disorder (EFO_0009963), Liver Disease (EFO_0001421), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.873 | Q17 | What gene does the drug Fulranumab target? | The drug Fulranumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NGF. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fulranumab%" OR LOWER(tradeNames_string) LIKE "%fulranumab%" OR LOWER(drugSynonyms_string) LIKE "%fulranumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5018', 'drugName': 'Fulranumab', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG 403, AMG-403, AMG403, Fulranumab, JNJ 42160443, JNJ-42160443', 'linkedDiseasesDrug_string': 'Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'NGF (ENSG00000134259)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.47 | Q17 | What gene does the drug Diclofenac Potassium target? | The drug Diclofenac Potassium targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diclofenac potassium%" OR LOWER(tradeNames_string) LIKE "%diclofenac potassium%" OR LOWER(drugSynonyms_string) LIKE "%diclofenac potassium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5263', 'drugName': 'Diclofenac Potassium', 'tradeNames_string': 'Cambia, Cataflam, Diclofenac potassium, Voltarol joint pain, Voltarol pain-eze, Voltarol pain-eze extra strgh, Voltarol rapid, Zipsor', 'drugSynonyms_string': 'CGP 45840B, CGP-45840B, Diclofenac potassium, Diclofenac potassium salt, Potassium diclofenac', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Pain (EFO_0003843), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Gastric Ulcer (EFO_0009454), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1388 | Q17 | What gene does the drug Ibalizumab target? | The drug Ibalizumab targets the gene CD4. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibalizumab%" OR LOWER(tradeNames_string) LIKE "%ibalizumab%" OR LOWER(drugSynonyms_string) LIKE "%ibalizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1583', 'drugName': 'Ibalizumab', 'tradeNames_string': 'Trogarzo', 'drugSynonyms_string': 'HU5A8, Ibalizumab, Ibalizumab-uiyk, TNX-355', 'linkedDiseasesDrug_string': 'Viral Disease (EFO_0000763), Hiv-1 Infection (EFO_0000180), Infection (EFO_0000544), Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD4 (ENSG00000010610)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1709 | Q17 | What gene does the drug Gemcitabine Hydrochloride target? | The drug Gemcitabine Hydrochloride targets 14 genes: POLD3, RRM2B, POLD1, POLE, POLD4, POLD2, PRIM2, RRM1, POLA1, PRIM1, RRM2, POLE3, POLA2 and POLE2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gemcitabine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%gemcitabine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%gemcitabine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugSynonyms_string': 'Gemcitabine (as hydrochloride), Gemcitabine hcl, Gemcitabine hydrochloride, Gemzar, LY-188011, LY-188011 HYDROCHLORIDE, LY188011 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}, {'UUID': 'DrugGeneTargets_v2_5', 'drugName': 'Gemcitabine Hydrochloride', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugSynonyms_string': 'Gemcitabine (as hydrochloride), Gemcitabine hcl, Gemcitabine hydrochloride, Gemzar, LY-188011, LY-188011 HYDROCHLORIDE, LY188011 HYDROCHLORIDE', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'numberLinkedTargets': 14}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1000 | Q17 | What gene does the drug Prazosin target? | The drug Prazosin targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prazosin%" OR LOWER(tradeNames_string) LIKE "%prazosin%" OR LOWER(drugSynonyms_string) LIKE "%prazosin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5385', 'drugName': 'Prazosin', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-12299, CP-122991, Prazosin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Post-Traumatic Stress Disorder (EFO_0001358), Methamphetamine Dependence (EFO_0004701), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Covid-19 (MONDO_0100096), Anxiety (EFO_0005230), Nephrolithiasis (EFO_0004253), Neurogenic Bladder (HP_0000011), Alcohol Withdrawal (EFO_0004777), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5265', 'drugName': 'Prazosin Hydrochloride', 'tradeNames_string': 'Alphavase 0.5, Alphavase 1, Alphavase 2, Alphavase 5, Hypovase, Hypovase b.d., Kentovace, Minipress, Minipress xl, Prazosin hydrochloride', 'drugSynonyms_string': 'CP-12,299-1, CP-12299-1, NSC-292810, Prazosin hcl, Prazosin hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.883 | Q17 | What gene does the drug Hupam4 target? | The drug Hupam4 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MUC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hupam4%" OR LOWER(tradeNames_string) LIKE "%hupam4%" OR LOWER(drugSynonyms_string) LIKE "%hupam4%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1450', 'drugName': 'Hupam4', 'tradeNames_string': '', 'drugSynonyms_string': 'HUPAM4', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MUC1 (ENSG00000185499)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.780 | Q17 | What gene does the drug Amlodipine Maleate target? | The drug Amlodipine Maleate targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amlodipine maleate%" OR LOWER(tradeNames_string) LIKE "%amlodipine maleate%" OR LOWER(drugSynonyms_string) LIKE "%amlodipine maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_352', 'drugName': 'Amlodipine Maleate', 'tradeNames_string': 'Amvaz', 'drugSynonyms_string': 'Amlodipine maleate, UK-48,340-11, UK-48340-11', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6132', 'drugName': 'Levamlodipine Maleate', 'tradeNames_string': 'Conjupri', 'drugSynonyms_string': 'Amlodipine maleate, s-, Levamlodipine maleate', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1229 | Q17 | What gene does the drug Diphenhydramine Hydrochloride target? | The drug Diphenhydramine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diphenhydramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%diphenhydramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%diphenhydramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2888', 'drugName': 'Diphenhydramine Hydrochloride', 'tradeNames_string': 'Alledryl, Antitussive, Beldin, Belix, Benadryl, Benadryl preservative free, Benylin, Caladryl, Coltex, Dibenil, Diphen, Diphenhydramine hydrochloride, Diphenhydramine hydrochloride preservative free, Dreemon, Dytuss, Fedril, Gppe cough expect paed, Gppe oral soln, Histergan, Hydramine, Medinex, Nightcalm, Nytol, Nytol one-a-night, Paxidorm, Silphen, Sleepia, Syntedril, Tixylix catarrh, Vicks formula 44', 'drugSynonyms_string': 'Dimedrol, Diphenhydramine HCl, Diphenhydramine hcl, Diphenhydramine hydrochloride, NSC-33299', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Orthostatic Hypotension (EFO_0005252), Headache (HP_0002315), Chronic Lymphocytic Leukemia (EFO_0000095), Diabetic Neuropathy (EFO_1000783), Breast Cancer (MONDO_0007254), Pain (EFO_0003843), Kidney Cancer (MONDO_0002367), Skin Disease (EFO_0000701), Systemic Lupus Erythematosus (MONDO_0007915), Allergic Rhinitis (EFO_0005854), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Disease (MONDO_0005271), Lupus Nephritis (EFO_0005761)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1015', 'drugName': 'Bromodiphenhydramine Hydrochloride', 'tradeNames_string': 'Ambodryl', 'drugSynonyms_string': 'Bromazine, Bromodiphenhydramine hcl, Bromodiphenhydramine hydrochloride, NSC-36113', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.2000 | Q17 | What gene does the drug Tolazoline Hydrochloride target? | The drug Tolazoline Hydrochloride targets 8 genes: ADRA2A, ADRA2C, HRH2, HRH1, ADRA1D, ADRA1B, ADRA2B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolazoline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tolazoline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tolazoline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2553', 'drugName': 'Tolazoline Hydrochloride', 'tradeNames_string': 'Benzidazol, Priscol, Priscoline', 'drugSynonyms_string': 'Benzazoline hydrochloride, NSC-757353, TCMDC-125842, Tolazoline HCl, Tolazoline hcl, Tolazoline hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), HRH2 (ENSG00000113749), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_2554', 'drugName': 'Tolazoline Hydrochloride', 'tradeNames_string': 'Benzidazol, Priscol, Priscoline', 'drugSynonyms_string': 'Benzazoline hydrochloride, NSC-757353, TCMDC-125842, Tolazoline HCl, Tolazoline hcl, Tolazoline hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), HRH2 (ENSG00000113749), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 8}, {'UUID': 'DrugGeneTargets_v2_2555', 'drugName': 'Tolazoline Hydrochloride', 'tradeNames_string': 'Benzidazol, Priscol, Priscoline', 'drugSynonyms_string': 'Benzazoline hydrochloride, NSC-757353, TCMDC-125842, Tolazoline HCl, Tolazoline hcl, Tolazoline hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639), HRH2 (ENSG00000113749), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 8}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.5 | Q17 | What gene does the drug Biperiden Hydrochloride target? | The drug Biperiden Hydrochloride targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%biperiden hydrochloride%" OR LOWER(tradeNames_string) LIKE "%biperiden hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%biperiden hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1550', 'drugName': 'Biperiden Hydrochloride', 'tradeNames_string': 'Akineton, Akineton ret', 'drugSynonyms_string': 'Akinophyl, Biperiden hcl, Biperiden hydrochloride, Biperideni hydrochloridum, NSC-170950, NSC-84989, Tasmolin', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1012 | Q17 | What gene does the drug Ciclesonide target? | The drug Ciclesonide targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ciclesonide%" OR LOWER(tradeNames_string) LIKE "%ciclesonide%" OR LOWER(drugSynonyms_string) LIKE "%ciclesonide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4432', 'drugName': 'Ciclesonide', 'tradeNames_string': 'Alvesco, Alvesco 160, Alvesco 80, Omnaris, Zetonna', 'drugSynonyms_string': 'BI54903, Ciclesonide, RPR-251526, RPR251526', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Chronic Rhinosinusitis (EFO_1000024), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Covid-19 (MONDO_0100096), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Allergic Rhinitis (EFO_0005854), Nasal Congestion (HP_0001742), Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1724 | Q17 | What gene does the drug Pegcantratinib target? | The drug Pegcantratinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NTRK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pegcantratinib%" OR LOWER(tradeNames_string) LIKE "%pegcantratinib%" OR LOWER(drugSynonyms_string) LIKE "%pegcantratinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2365', 'drugName': 'Pegcantratinib', 'tradeNames_string': '', 'drugSynonyms_string': 'CT-327, CT327, Ct-327, Pegcantratinib, SNA-120, Sna-120', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Atopic Eczema (EFO_0000274), Psoriasis Vulgaris (EFO_1001494), Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'NTRK1 (ENSG00000198400)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.266 | Q17 | What gene does the drug Flindokalner target? | The drug Flindokalner is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: KCNQ4, KCNMA1, KCNQ3, KCNQ5 and KCNQ2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flindokalner%" OR LOWER(tradeNames_string) LIKE "%flindokalner%" OR LOWER(drugSynonyms_string) LIKE "%flindokalner%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2869', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2865', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2864', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2867', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2868', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2866', 'drugName': 'Flindokalner', 'tradeNames_string': 'Maxipost', 'drugSynonyms_string': 'BMS-204352, BMS-204352-01, Flindokalner', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'KCNMA1 (ENSG00000156113), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNQ4 (ENSG00000117013), KCNQ5 (ENSG00000185760)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1570 | Q17 | What gene does the drug Fostamatinib Disodium target? | The drug Fostamatinib Disodium targets the gene SYK. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fostamatinib disodium%" OR LOWER(tradeNames_string) LIKE "%fostamatinib disodium%" OR LOWER(drugSynonyms_string) LIKE "%fostamatinib disodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4030', 'drugName': 'Fostamatinib Disodium', 'tradeNames_string': 'Tavalisse', 'drugSynonyms_string': 'Fostamatinib disodium, Fostamatinib disodium hexahydrate, Fostamatinib disodium salt hexahydrate, Fostamatinib sodium hydrate, R-788 SODIUM, R-788 SODIUM HYDRATE, R-935788 SODIUM, R-935788 SODIUM HYDRATE, R788 SODIUM, R788 SODIUM HYDRATE, R935788 SODIUM, R935788 SODIUM HYDRATE', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Anemia, Hemolytic, Autoimmune (EFO_1001264), Lymphoma (EFO_0000574), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SYK (ENSG00000165025)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1832 | Q17 | What gene does the drug Amg-108 target? | The drug Amg-108 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL1R1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amg-108%" OR LOWER(tradeNames_string) LIKE "%amg-108%" OR LOWER(drugSynonyms_string) LIKE "%amg-108%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_714', 'drugName': 'Amg-108', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG-108, Amg-108', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Osteoarthritis (MONDO_0005178), Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL1R1 (ENSG00000115594)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.449 | Q17 | What gene does the drug Estrone Sulfuric Acid target? | The drug Estrone Sulfuric Acid targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estrone sulfuric acid%" OR LOWER(tradeNames_string) LIKE "%estrone sulfuric acid%" OR LOWER(drugSynonyms_string) LIKE "%estrone sulfuric acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2018', 'drugName': 'Estrone Sulfuric Acid', 'tradeNames_string': '', 'drugSynonyms_string': 'Estrone Sulphate', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Atrophy (EFO_1000096), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1011 | Q17 | What gene does the drug Bromodiphenhydramine Hydrochloride target? | The drug Bromodiphenhydramine Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bromodiphenhydramine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%bromodiphenhydramine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%bromodiphenhydramine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1015', 'drugName': 'Bromodiphenhydramine Hydrochloride', 'tradeNames_string': 'Ambodryl', 'drugSynonyms_string': 'Bromazine, Bromodiphenhydramine hcl, Bromodiphenhydramine hydrochloride, NSC-36113', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1086 | Q17 | What gene does the drug Mesoridazine Besylate target? | The drug Mesoridazine Besylate targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mesoridazine besylate%" OR LOWER(tradeNames_string) LIKE "%mesoridazine besylate%" OR LOWER(drugSynonyms_string) LIKE "%mesoridazine besylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3633', 'drugName': 'Mesoridazine Besylate', 'tradeNames_string': 'Serentil', 'drugSynonyms_string': 'Mesoridazine benzenesulfonate, Mesoridazine besilate, Mesoridazine besylate, NSC-760073', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3634', 'drugName': 'Mesoridazine Besylate', 'tradeNames_string': 'Serentil', 'drugSynonyms_string': 'Mesoridazine benzenesulfonate, Mesoridazine besilate, Mesoridazine besylate, NSC-760073', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.844 | Q17 | What gene does the drug Methaqualone target? | The drug Methaqualone targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methaqualone%" OR LOWER(tradeNames_string) LIKE "%methaqualone%" OR LOWER(drugSynonyms_string) LIKE "%methaqualone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2025', 'drugName': 'Methaqualone Hydrochloride', 'tradeNames_string': 'Optimil, Parest', 'drugSynonyms_string': 'Methaqualone hcl, Methaqualone hydrochloride, NSC-75892', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_4173', 'drugName': 'Methaqualone', 'tradeNames_string': '', 'drugSynonyms_string': 'CI-705, CN 38703, CN-38703, Methaqualone, Methaqualoneinone, Metolquizolone, NSC-111388, NSC-111388-, NSC-126877, NSC-631628, QZ-2, R-148, TR-495', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1792 | Q17 | What gene does the drug Oxtriphylline target? | The drug Oxtriphylline targets 10 genes: PDE4D, PDE3B, ADORA2B, PDE3A, PDE4B, ADORA1, PDE4A, ADORA3, PDE4C and ADORA2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxtriphylline%" OR LOWER(tradeNames_string) LIKE "%oxtriphylline%" OR LOWER(drugSynonyms_string) LIKE "%oxtriphylline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3797', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3798', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3799', 'drugName': 'Oxtriphylline', 'tradeNames_string': 'Choledyl, Choledyl sa, Oxtriphylline, Oxtriphylline pediatric, Sabidal', 'drugSynonyms_string': 'Choline theophyllinate, Choline theophylline, Cholinophyllin, NSC-760431, Oxtriphylline, Theocolin', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDE3A (ENSG00000172572), PDE3B (ENSG00000152270), PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.308 | Q17 | What gene does the drug Alendronic Acid target? | The drug Alendronic Acid targets the gene FDPS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alendronic acid%" OR LOWER(tradeNames_string) LIKE "%alendronic acid%" OR LOWER(drugSynonyms_string) LIKE "%alendronic acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4741', 'drugName': 'Alendronate Sodium', 'tradeNames_string': 'Alendronate sodium, Binosto, Fosamax', 'drugSynonyms_string': 'Adrovance, Alendronate (as sodium), Alendronate sodium, Alendronate sodium hydrate, Alendronate sodium trihydrate, Alendronic acid monosodium salt trihydrate, Fosavance, G-704,650, G-704650, MK-217, NSC-722597, NSC-758931, Sodium alendronate, Sodium alendronate trihydrate, Vantavo', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Vitamin D Deficiency (EFO_0003762), Osteitis Deformans (EFO_0004261), Metabolic Disease (EFO_0000589)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5882', 'drugName': 'Alendronic Acid', 'tradeNames_string': 'Binosto, Fosamax', 'drugSynonyms_string': 'Alendronate, Alendronic Acid, Alendronic acid, Fosamax', 'linkedDiseasesDrug_string': 'Postmenopausal Osteoporosis (EFO_0003854), Coronary Stenosis (MONDO_0006715), Metabolic Disease (EFO_0000589), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Osteoporosis (EFO_0003882), Bone Disease (EFO_0004260), Osteopenia (HP_0000938), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Hepatitis B Virus Infection (EFO_0004197), Vitamin D Deficiency (EFO_0003762), Osteitis Deformans (EFO_0004261), Periodontitis (EFO_0000649), Asthma (MONDO_0004979), Aortic Stenosis (EFO_0000266), Osteoarthritis (MONDO_0005178), Hiv Infection (EFO_0000764), Polyostotic Fibrous Dysplasia (MONDO_0008274)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1380 | Q17 | What gene does the drug Sabatolimab target? | The drug Sabatolimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HAVCR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sabatolimab%" OR LOWER(tradeNames_string) LIKE "%sabatolimab%" OR LOWER(drugSynonyms_string) LIKE "%sabatolimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2775', 'drugName': 'Sabatolimab', 'tradeNames_string': '', 'drugSynonyms_string': 'MBG-453, MBG453, Mbg 453, Mbg453, NVP-MBG453, Sabatolimab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Myelofibrosis (MONDO_0044903), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HAVCR2 (ENSG00000135077)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1558 | Q17 | What gene does the drug Prilocaine target? | The drug Prilocaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prilocaine%" OR LOWER(tradeNames_string) LIKE "%prilocaine%" OR LOWER(drugSynonyms_string) LIKE "%prilocaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3212', 'drugName': 'Prilocaine', 'tradeNames_string': '', 'drugSynonyms_string': 'ASTRA-1512, ASTRA-1515, Citanest, NSC-40027, Prilocaine, Propitocaine', 'linkedDiseasesDrug_string': 'Squamous Cell Carcinoma (EFO_0000707), Postherpetic Neuralgia (MONDO_0041052), Pain (EFO_0003843), Chronic Pain (HP_0012532), Actinic Keratosis (EFO_0002496), Skin Disease (EFO_0000701), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_281', 'drugName': 'Prilocaine Hydrochloride', 'tradeNames_string': 'Citanest, Citanest plain, Citanest plain dental, Prilocaine hydrochloride', 'drugSynonyms_string': 'ASTRA 1512, Citanest hydrochloride, L-67, NSC-758432, Prilocaine hcl, Prilocaine hydrochloride, Propitocaine hydrochloride, Xylonest', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.317 | Q17 | What gene does the drug Vanutide Cridificar target? | The drug Vanutide Cridificar is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene APP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vanutide cridificar%" OR LOWER(tradeNames_string) LIKE "%vanutide cridificar%" OR LOWER(drugSynonyms_string) LIKE "%vanutide cridificar%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3156', 'drugName': 'Vanutide Cridificar', 'tradeNames_string': '', 'drugSynonyms_string': 'ACC-001, Vanutide cridificar', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.152 | Q17 | What gene does the drug Gefitinib target? | The drug Gefitinib targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gefitinib%" OR LOWER(tradeNames_string) LIKE "%gefitinib%" OR LOWER(drugSynonyms_string) LIKE "%gefitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4972', 'drugName': 'Gefitinib', 'tradeNames_string': 'Iressa', 'drugSynonyms_string': 'Gefitinib, Iressa, NSC-759856, ZD-1839, ZD1839', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Skin Cancer (MONDO_0002898), Peritoneal Neoplasm (EFO_1001100), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Squamous Cell Lung Carcinoma (EFO_0000708), Lung Carcinoma (EFO_0001071), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Uterine Neoplasm (EFO_0003859), Male Breast Carcinoma (EFO_0006861), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Gastric Carcinoma (EFO_0000178), Urethra Cancer (MONDO_0004192), Bronchoalveolar Adenocarcinoma (EFO_0000308), Central Nervous System Neoplasm (EFO_1000158), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Salivary Gland Cancer (MONDO_0004669), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Lung Cancer (MONDO_0008903), Urinary Bladder Cancer (MONDO_0001187), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Glioblastoma Multiforme (EFO_0000519), Stomach Neoplasm (EFO_0003897), Esophageal Cancer (MONDO_0007576), Germ Cell Tumor (EFO_0000514)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1158 | Q17 | What gene does the drug Vincristine Sulfate target? | The drug Vincristine Sulfate targets 15 genes: TUBB, TUBA4A, TUBA3E, TUBB3, TUBB4B, TUBB2A, TUBA1A, TUBA1C, TUBB1, TUBB2B, TUBB8, TUBB6, TUBB4A, TUBA3C and TUBA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vincristine sulfate%" OR LOWER(tradeNames_string) LIKE "%vincristine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%vincristine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3353', 'drugName': 'Vincristine Sulfate', 'tradeNames_string': 'Kyocristine, Leurocristine Sulfate, Marqibo kit, Oncovin, Vincasar, Vincasar pfs, Vincrex, Vincristine sulfate, Vincristine sulfate pfs', 'drugSynonyms_string': '37231, Kyocristine, LILLY-37231, Marqibo, NSC-67574, Novopharm, Vincristine sulfate, Vincristine sulfate liposome, Vincristine sulphate, Vincristini sulfas, Vincrisul', 'linkedDiseasesDrug_string': "Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Medulloblastoma (EFO_0002939), Chronic Lymphocytic Leukemia (EFO_0000095), Non-Hodgkins Lymphoma (EFO_0005952), Anaplastic Large Cell Lymphoma (EFO_0003032), Hemophagocytic Syndrome (MONDO_0015540), Aids (EFO_0000765), Burkitts Lymphoma (EFO_0000309), Hepatoblastoma (EFO_1000292), Colorectal Carcinoma (EFO_1001951), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Astrocytoma (EFO_0000272), Mantle Cell Lymphoma (EFO_1001469), Embryonal Rhabdomyosarcoma (EFO_0000437), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloid Leukemia (EFO_0000222), Wilms Tumor (MONDO_0006058), Diffuse Large B-Cell Lymphoma (EFO_0000403), Central Nervous System Neoplasm (EFO_1000158), Retinoblastoma (MONDO_0008380), Rhabdomyosarcoma (EFO_0002918), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Brain Neoplasm (EFO_0003833), Waldenstrom Macroglobulinemia (EFO_0009441), Carcinoma (EFO_0000313), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), T-Lymphoblastic Lymphoma (MONDO_0044917), Lymphoid Leukemia (EFO_0004289), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Mesenchymoma (EFO_1001042), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Classic Hodgkin Lymphoma (MONDO_0009348), Lymphoma, Aids-Related (EFO_1001365), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Primitive Neuroectodermal Tumor (EFO_0005235), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'numberLinkedTargets': 15}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1223 | Q17 | What gene does the drug Acetylcholine target? | The drug Acetylcholine targets the gene CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acetylcholine%" OR LOWER(tradeNames_string) LIKE "%acetylcholine%" OR LOWER(drugSynonyms_string) LIKE "%acetylcholine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5629', 'drugName': 'Acetylcholine', 'tradeNames_string': '', 'drugSynonyms_string': 'Acetylcholine', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Hiv Infection (EFO_0000764), Anemia (Phenotype) (EFO_0004272), Cataract (MONDO_0005129), Miosis (HP_0000616), Obesity (EFO_0001073), Sickle Cell Anemia (MONDO_0011382), Inflammation (MP_0001845), Glaucoma (MONDO_0005041), Type 2 Diabetes Mellitus (MONDO_0005148), Ischemia (EFO_0000556)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3911', 'drugName': 'Acetylcholine Chloride', 'tradeNames_string': 'Miochol, Miochol-e, Miphtel', 'drugSynonyms_string': 'Acetylcholine, Acetylcholine Chloride, Acetylcholine chloride, Acetylcholine chloride for injection, Choline acetate (ester) chloride, Miochol, Miochol-E, NSC-755845', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Miosis (HP_0000616)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.580 | Q17 | What gene does the drug Gsk933776 target? | The drug Gsk933776 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene APP. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gsk933776%" OR LOWER(tradeNames_string) LIKE "%gsk933776%" OR LOWER(drugSynonyms_string) LIKE "%gsk933776%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5607', 'drugName': 'Gsk933776', 'tradeNames_string': '', 'drugSynonyms_string': 'GSK933776, Gsk933776', 'linkedDiseasesDrug_string': 'Atrophic Macular Degeneration (EFO_1001492), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'APP (ENSG00000142192)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.51 | Q17 | What gene does the drug Zalunfiban target? | The drug Zalunfiban is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ITGB3 and ITGA2B | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zalunfiban%" OR LOWER(tradeNames_string) LIKE "%zalunfiban%" OR LOWER(drugSynonyms_string) LIKE "%zalunfiban%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5059', 'drugName': 'Zalunfiban', 'tradeNames_string': '', 'drugSynonyms_string': 'RUC-4, Zalunfiban', 'linkedDiseasesDrug_string': 'St Elevation Myocardial Infarction (EFO_0008585), Coronary Artery Disease (EFO_0001645)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1553 | Q17 | What gene does the drug Atezolizumab target? | The drug Atezolizumab targets the gene CD274. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%atezolizumab%" OR LOWER(tradeNames_string) LIKE "%atezolizumab%" OR LOWER(drugSynonyms_string) LIKE "%atezolizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_449', 'drugName': 'Atezolizumab', 'tradeNames_string': 'Tecentriq', 'drugSynonyms_string': '0ine2sfd9e, Anti-PD-L1, Anti-PDL1, Atezolizumab, MPDL-3280A, MPDL3280A, RG-7446, RG7446', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Small Cell Carcinoma (EFO_0008524), Papillary Renal Cell Carcinoma (EFO_0000640), Liver Neoplasm (EFO_1001513), Gallbladder Carcinoma (EFO_1001956), Malignant Glioma (MONDO_0100342), Carcinoma (EFO_0000313), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Follicular Lymphoma (MONDO_0018906), Lung Cancer (MONDO_0008903), Anus Cancer (MONDO_0001879), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Gastric Adenocarcinoma (EFO_0000503), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Alveolar Soft Part Sarcoma (EFO_0007143), Thyroid Carcinoma (EFO_0002892), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Malignant Peritoneal Mesothelioma (EFO_0005567), Colorectal Neoplasm (EFO_0004142), Cervical Carcinoma (EFO_0001061), Endometrial Carcinoma (EFO_1001512), Renal Cell Carcinoma (EFO_0000681), Ovarian Neoplasm (EFO_0003893), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD274 (ENSG00000120217)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.733 | Q17 | What gene does the drug Idarubicin Hydrochloride target? | The drug Idarubicin Hydrochloride targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%idarubicin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%idarubicin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%idarubicin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5440', 'drugName': 'Idarubicin Hydrochloride', 'tradeNames_string': 'Idamycin, Idamycin pfs, Idarubicin hydrochloride, Idarubicin hydrochloride pfs, Zavedos', 'drugSynonyms_string': 'IMI 30, IMI-30, Idarubicin hcl, Idarubicin hydrochloride, NSC-256439', 'linkedDiseasesDrug_string': 'Hepatocellular Carcinoma (EFO_0000182), Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.840 | Q17 | What gene does the drug Daunorubicin Citrate target? | The drug Daunorubicin Citrate targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daunorubicin citrate%" OR LOWER(tradeNames_string) LIKE "%daunorubicin citrate%" OR LOWER(drugSynonyms_string) LIKE "%daunorubicin citrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1471', 'drugName': 'Daunorubicin Citrate', 'tradeNames_string': 'Daunoxome', 'drugSynonyms_string': 'Daunorubicin citrate, Daunorubicin citrate liposome, Daunorubicin liposomal', 'linkedDiseasesDrug_string': 'Leukemia (EFO_0000565), Breast Cancer (MONDO_0007254), Sarcoma (EFO_0000691)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1392 | Q17 | What gene does the drug Orn-0829 Hydrate target? | The drug Orn-0829 Hydrate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: HCRTR2 and HCRTR1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%orn-0829 hydrate%" OR LOWER(tradeNames_string) LIKE "%orn-0829 hydrate%" OR LOWER(drugSynonyms_string) LIKE "%orn-0829 hydrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3792', 'drugName': 'Orn-0829 Hydrate', 'tradeNames_string': '', 'drugSynonyms_string': 'ORN-0829 HYDRATE, ORN0829 HYDRATE, Orn-0829 hydrate, Ts-142', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1125 | Q17 | What gene does the drug Reparixin target? | The drug Reparixin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: CXCR1 and CXCR2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%reparixin%" OR LOWER(tradeNames_string) LIKE "%reparixin%" OR LOWER(drugSynonyms_string) LIKE "%reparixin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2753', 'drugName': 'Reparixin', 'tradeNames_string': '', 'drugSynonyms_string': 'DF 1681Y, DF-1681Y, DF1681Y, Df-1681y, Reparixin, Repertaxin', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Ischemia Reperfusion Injury (EFO_0002687), Pneumonia (EFO_0003106), Viral Pneumonia (EFO_0007541), Covid-19 (MONDO_0100096), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Chronic Pancreatitis (EFO_0000342), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCR1 (ENSG00000163464), CXCR2 (ENSG00000180871)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2754', 'drugName': 'Reparixin', 'tradeNames_string': '', 'drugSynonyms_string': 'DF 1681Y, DF-1681Y, DF1681Y, Df-1681y, Reparixin, Repertaxin', 'linkedDiseasesDrug_string': 'Breast Cancer (MONDO_0007254), Ischemia Reperfusion Injury (EFO_0002687), Pneumonia (EFO_0003106), Viral Pneumonia (EFO_0007541), Covid-19 (MONDO_0100096), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Chronic Pancreatitis (EFO_0000342), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCR1 (ENSG00000163464), CXCR2 (ENSG00000180871)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1176 | Q17 | What gene does the drug Decernotinib target? | The drug Decernotinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene JAK3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%decernotinib%" OR LOWER(tradeNames_string) LIKE "%decernotinib%" OR LOWER(drugSynonyms_string) LIKE "%decernotinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3193', 'drugName': 'Decernotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Adelatinib, Decernotinib, VRT-831509, VX-509', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'JAK3 (ENSG00000105639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.476 | Q17 | What gene does the drug Rilonacept target? | The drug Rilonacept targets the gene IL1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rilonacept%" OR LOWER(tradeNames_string) LIKE "%rilonacept%" OR LOWER(drugSynonyms_string) LIKE "%rilonacept%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3681', 'drugName': 'Rilonacept', 'tradeNames_string': 'Arcalyst', 'drugSynonyms_string': 'IL-1 TRAP, IL-1-TRAP, INTERLEUKIN-1 TRAP, KPL-914, Kpl-914, Rilonacept', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hepatitis, Alcoholic (EFO_1001345), Muckle-Wells Syndrome (MONDO_0008633), Juvenile Idiopathic Arthritis (EFO_0002609), Pericarditis (EFO_0007427), Hearing Loss (EFO_0004238), Cryopyrin-Associated Periodic Syndrome (MONDO_0016168), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540), Familial Mediterranean Fever (MONDO_0018088), Familial Cold Urticaria (Orphanet_47045), Diffuse Scleroderma (EFO_0000404)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL1B (ENSG00000125538)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.980 | Q17 | What gene does the drug Methyclothiazide target? | The drug Methyclothiazide targets the gene SLC12A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methyclothiazide%" OR LOWER(tradeNames_string) LIKE "%methyclothiazide%" OR LOWER(drugSynonyms_string) LIKE "%methyclothiazide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_926', 'drugName': 'Methyclothiazide', 'tradeNames_string': 'Aquatensen, Enduron, Methyclothiazide', 'drugSynonyms_string': 'Methyclothiazide, NSC-110431', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A3 (ENSG00000070915)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.660 | Q17 | What gene does the drug Quetiapine target? | The drug Quetiapine targets 3 genes: HTR2C, HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quetiapine%" OR LOWER(tradeNames_string) LIKE "%quetiapine%" OR LOWER(drugSynonyms_string) LIKE "%quetiapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6236', 'drugName': 'Quetiapine', 'tradeNames_string': 'Atrolak xl, Biquelle xl, Brancico xl, Ebesque xl, Mintreleq xl, Psyquet xl, Seotiapim xl, Seroquel, Seroquel xl, Sondate xl, Tenprolide xl, Zaluron xl', 'drugSynonyms_string': 'NSC-758918, Norsic, Quetiapine, Quetiapine extended release', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Cannabis Dependence (EFO_0007191), Anorexia Nervosa (MONDO_0005351), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Postpartum Depression (EFO_0007453), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Fish-Eye Disease (Orphanet_79292), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Neurotic Disorder (EFO_0004257), Treatment Resistant Depression (EFO_0009854), Methamphetamine Dependence (EFO_0004701), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Mental Or Behavioural Disorder (EFO_0000677), Borderline Personality Disorder (HP_0012076), Delirium (EFO_0009267), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Chronic Kidney Disease (EFO_0003884), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4442', 'drugName': 'Quetiapine Fumarate', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Neurotic Disorder (EFO_0004257), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Borderline Personality Disorder (HP_0012076), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4441', 'drugName': 'Quetiapine Fumarate', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Neurotic Disorder (EFO_0004257), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Borderline Personality Disorder (HP_0012076), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6234', 'drugName': 'Quetiapine', 'tradeNames_string': 'Atrolak xl, Biquelle xl, Brancico xl, Ebesque xl, Mintreleq xl, Psyquet xl, Seotiapim xl, Seroquel, Seroquel xl, Sondate xl, Tenprolide xl, Zaluron xl', 'drugSynonyms_string': 'NSC-758918, Norsic, Quetiapine, Quetiapine extended release', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Cannabis Dependence (EFO_0007191), Anorexia Nervosa (MONDO_0005351), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Postpartum Depression (EFO_0007453), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Fish-Eye Disease (Orphanet_79292), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Neurotic Disorder (EFO_0004257), Treatment Resistant Depression (EFO_0009854), Methamphetamine Dependence (EFO_0004701), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Mental Or Behavioural Disorder (EFO_0000677), Borderline Personality Disorder (HP_0012076), Delirium (EFO_0009267), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Chronic Kidney Disease (EFO_0003884), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6235', 'drugName': 'Quetiapine', 'tradeNames_string': 'Atrolak xl, Biquelle xl, Brancico xl, Ebesque xl, Mintreleq xl, Psyquet xl, Seotiapim xl, Seroquel, Seroquel xl, Sondate xl, Tenprolide xl, Zaluron xl', 'drugSynonyms_string': 'NSC-758918, Norsic, Quetiapine, Quetiapine extended release', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Cannabis Dependence (EFO_0007191), Anorexia Nervosa (MONDO_0005351), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Postpartum Depression (EFO_0007453), Mood Disorder (EFO_0004247), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Fish-Eye Disease (Orphanet_79292), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Cocaine Dependence (EFO_0002610), Neurotic Disorder (EFO_0004257), Treatment Resistant Depression (EFO_0009854), Methamphetamine Dependence (EFO_0004701), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Mental Or Behavioural Disorder (EFO_0000677), Borderline Personality Disorder (HP_0012076), Delirium (EFO_0009267), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Chronic Kidney Disease (EFO_0003884), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_4443', 'drugName': 'Quetiapine Fumarate', 'tradeNames_string': 'Quetiapine fumarate, Seroquel, Seroquel xr', 'drugSynonyms_string': 'FK-947E, FK947E, ICI 204,636, ICI-204636, Quetiapine (as fumarate), Quetiapine fumarate, Quetiapine hemifumarate, Utapine, ZD-5077, ZD5077, ZM 204,636, ZM-204636', 'linkedDiseasesDrug_string': 'Bipolar I Disorder (EFO_0009963), Multiple Sclerosis (MONDO_0005301), Agitation (HP_0000713), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Schizoaffective Disorder (EFO_0005411), Dementia (HP_0000726), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Neurotic Disorder (EFO_0004257), Bipolar Ii Disorder (EFO_0009964), Obsessive-Compulsive Disorder (EFO_0004242), Borderline Personality Disorder (HP_0012076), Generalized Anxiety Disorder (EFO_1001892), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Social Anxiety Disorder (EFO_1001917), Alcohol Dependence (MONDO_0007079), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.405 | Q17 | What gene does the drug Sulpiride target? | The drug Sulpiride targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sulpiride%" OR LOWER(tradeNames_string) LIKE "%sulpiride%" OR LOWER(drugSynonyms_string) LIKE "%sulpiride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5185', 'drugName': 'Sulpiride', 'tradeNames_string': 'Dogmatyl, Dolmatil', 'drugSynonyms_string': 'N05AL01, NSC-757850, RD-1403, Sulpiride', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1938', 'drugName': 'Levosulpiride', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-sulpiride, L-sulpiride, Lesuride, Levobren, Levopraid, Levopride, Levosulpiride, S-(-)-sulpiride, Sulpiride l-form, Sulpiride, (-)-, Sulpiride, (s)-', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Agitation (HP_0000713), Dyspepsia (EFO_0008533)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1939', 'drugName': 'Levosulpiride', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-sulpiride, L-sulpiride, Lesuride, Levobren, Levopraid, Levopride, Levosulpiride, S-(-)-sulpiride, Sulpiride l-form, Sulpiride, (-)-, Sulpiride, (s)-', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Agitation (HP_0000713), Dyspepsia (EFO_0008533)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR4 (ENSG00000164270), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.517 | Q17 | What gene does the drug Mephentermine target? | The drug Mephentermine targets 9 genes: ADRA2A, ADRB1, ADRA2C, ADRA1A, ADRA1D, ADRA1B, ADRB3, ADRA2B and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mephentermine%" OR LOWER(tradeNames_string) LIKE "%mephentermine%" OR LOWER(drugSynonyms_string) LIKE "%mephentermine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4567', 'drugName': 'Mephentermine', 'tradeNames_string': '', 'drugSynonyms_string': 'Mephentermine', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_4285', 'drugName': 'Mephentermine Sulfate', 'tradeNames_string': 'Wyamine sulfate', 'drugSynonyms_string': 'Mephentermine sulfate, Mephentermine sulfate dihydrate, Mephentermine sulphate, Mephine, NSC-758424, Wyamine, Wyamine sulphate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1951, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 9}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.324 | Q17 | What gene does the drug Benzydamine Hydrochloride target? | The drug Benzydamine Hydrochloride targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benzydamine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%benzydamine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%benzydamine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3576', 'drugName': 'Benzydamine Hydrochloride', 'tradeNames_string': 'Difflam, Difflam-p, Lozamine, Tantum', 'drugSynonyms_string': 'AF-864, Benzidamine hydrochloride, Benzydamine hcl, Benzydamine hydrochloride, NSC-759276', 'linkedDiseasesDrug_string': 'Oral Mucositis (EFO_1001904), Stomatitis (EFO_0009688)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.20 | Q17 | What gene does the drug Ly2881835 target? | The drug Ly2881835 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FFAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ly2881835%" OR LOWER(tradeNames_string) LIKE "%ly2881835%" OR LOWER(drugSynonyms_string) LIKE "%ly2881835%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5831', 'drugName': 'Ly2881835', 'tradeNames_string': '', 'drugSynonyms_string': 'LY-2881835, LY2881835, Ly2881835', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FFAR1 (ENSG00000126266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.691 | Q17 | What gene does the drug Clevidipine target? | The drug Clevidipine targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clevidipine%" OR LOWER(tradeNames_string) LIKE "%clevidipine%" OR LOWER(drugSynonyms_string) LIKE "%clevidipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_250', 'drugName': 'Clevidipine', 'tradeNames_string': 'Cleviprex', 'drugSynonyms_string': 'Clevidepine, Clevidepine butyrate, Clevidipine, Clevidipine butyrate', 'linkedDiseasesDrug_string': 'Malignant Hypertension (EFO_1001031), Stroke (EFO_0000712), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Vascular Disease (EFO_0004264), Scoliosis (EFO_0004273)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.36 | Q17 | What gene does the drug Dostarlimab target? | The drug Dostarlimab targets the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dostarlimab%" OR LOWER(tradeNames_string) LIKE "%dostarlimab%" OR LOWER(drugSynonyms_string) LIKE "%dostarlimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6044', 'drugName': 'Dostarlimab', 'tradeNames_string': 'Jemperli', 'drugSynonyms_string': 'Dostarlimab, Dostarlimab gxly, Dostarlimab-gxly, GSK-4057190, GSK4057190, TSR-042, Tsr 042, Tsr-042, WBP-285', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Gestational Trophoblastic Neoplasm (MONDO_0018944), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Malignant Colon Neoplasm (MONDO_0021063), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Cervical Carcinoma (EFO_0001061), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Liver Cancer (MONDO_0002691), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.910 | Q17 | What gene does the drug Dextromethorphan Hydrobromide target? | The drug Dextromethorphan Hydrobromide targets 2 genes: GRIN2A and SIGMAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dextromethorphan hydrobromide%" OR LOWER(tradeNames_string) LIKE "%dextromethorphan hydrobromide%" OR LOWER(drugSynonyms_string) LIKE "%dextromethorphan hydrobromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5995', 'drugName': 'Dextromethorphan Hydrobromide', 'tradeNames_string': 'Beecham coughcaps, Benylin dm, Brontyl, Contac coughcaps, Delsym, Dextromethorphan hydrobromide oros tablets, Drixoral cough, Franolyn dry, Franolyn sed, Pediacare 1, Romilar, Tussabron, Tuxium', 'drugSynonyms_string': 'Dextromethorphan Hydrobromide Monohydrate, Dextromethorphan hydrobromide, NSC-756723', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Headache (HP_0002315), Common Cold (EFO_0007214), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Pain (EFO_0003843), Fever (HP_0001945), Cough (HP_0012735), Migraine Disorder (MONDO_0005277), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Nasal Congestion (HP_0001742), Type 2 Diabetes Mellitus (MONDO_0005148), Allergic Disease (MONDO_0005271), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN2A (ENSG00000183454), SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5996', 'drugName': 'Dextromethorphan Hydrobromide', 'tradeNames_string': 'Beecham coughcaps, Benylin dm, Brontyl, Contac coughcaps, Delsym, Dextromethorphan hydrobromide oros tablets, Drixoral cough, Franolyn dry, Franolyn sed, Pediacare 1, Romilar, Tussabron, Tuxium', 'drugSynonyms_string': 'Dextromethorphan Hydrobromide Monohydrate, Dextromethorphan hydrobromide, NSC-756723', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Headache (HP_0002315), Common Cold (EFO_0007214), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Pain (EFO_0003843), Fever (HP_0001945), Cough (HP_0012735), Migraine Disorder (MONDO_0005277), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Nasal Congestion (HP_0001742), Type 2 Diabetes Mellitus (MONDO_0005148), Allergic Disease (MONDO_0005271), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GRIN2A (ENSG00000183454), SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.834 | Q17 | What gene does the drug Estropipate target? | The drug Estropipate targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estropipate%" OR LOWER(tradeNames_string) LIKE "%estropipate%" OR LOWER(drugSynonyms_string) LIKE "%estropipate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2257', 'drugName': 'Estropipate', 'tradeNames_string': 'Estropipate, Harmogen, Ogen, Ogen .625, Ogen 1.25, Ogen 2.5, Ogen 5, Ortho-est', 'drugSynonyms_string': 'Estrone sulfate piperazine salt, Estropipate, NSC-758912, Piperazine estrone sulfate, Piperazine estrone sulphate, Sulestrex piperazine', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Hypogonadism (MONDO_0002146), Menopause (EFO_0003922), Atrophy (EFO_1000096), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1798 | Q17 | What gene does the drug Esmolol target? | The drug Esmolol targets 2 genes: ADRB2 and ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esmolol%" OR LOWER(tradeNames_string) LIKE "%esmolol%" OR LOWER(drugSynonyms_string) LIKE "%esmolol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5672', 'drugName': 'Esmolol', 'tradeNames_string': '', 'drugSynonyms_string': 'ASL-8052-001, Esmolol', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Coronary Artery Disease (EFO_0001645), Cognitive Impairment (HP_0100543), Ischemia Reperfusion Injury (EFO_0002687), Septic Shock (EFO_0006834), Brain Aneurysm (EFO_0003870), Pain (EFO_0003843), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Brain Neoplasm (EFO_0003833), Diabetic Foot (EFO_1001459), Ovarian Cyst (HP_0000138), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5671', 'drugName': 'Esmolol', 'tradeNames_string': '', 'drugSynonyms_string': 'ASL-8052-001, Esmolol', 'linkedDiseasesDrug_string': 'Sinusitis (EFO_0007486), Coronary Artery Disease (EFO_0001645), Cognitive Impairment (HP_0100543), Ischemia Reperfusion Injury (EFO_0002687), Septic Shock (EFO_0006834), Brain Aneurysm (EFO_0003870), Pain (EFO_0003843), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Brain Neoplasm (EFO_0003833), Diabetic Foot (EFO_1001459), Ovarian Cyst (HP_0000138), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4942', 'drugName': 'Esmolol Hydrochloride', 'tradeNames_string': 'Brevibloc, Esmolol hydrochloride', 'drugSynonyms_string': 'ASL-8052, Esmolol hcl, Esmolol hydrochloride', 'linkedDiseasesDrug_string': 'Cognitive Impairment (HP_0100543), Septic Shock (EFO_0006834), Hypertension (EFO_0000537), Diabetic Foot (EFO_1001459), Ovarian Cyst (HP_0000138)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4941', 'drugName': 'Esmolol Hydrochloride', 'tradeNames_string': 'Brevibloc, Esmolol hydrochloride', 'drugSynonyms_string': 'ASL-8052, Esmolol hcl, Esmolol hydrochloride', 'linkedDiseasesDrug_string': 'Cognitive Impairment (HP_0100543), Septic Shock (EFO_0006834), Hypertension (EFO_0000537), Diabetic Foot (EFO_1001459), Ovarian Cyst (HP_0000138)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.413 | Q17 | What gene does the drug L19Tnfa target? | The drug L19Tnfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FN1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%l19tnfa%" OR LOWER(tradeNames_string) LIKE "%l19tnfa%" OR LOWER(drugSynonyms_string) LIKE "%l19tnfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3095', 'drugName': 'L19Tnfa', 'tradeNames_string': '', 'drugSynonyms_string': 'L19TNFA, L19tnfa', 'linkedDiseasesDrug_string': 'Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FN1 (ENSG00000115414)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.928 | Q17 | What gene does the drug Benoxaprofen target? | The drug Benoxaprofen targets the gene ALOX12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benoxaprofen%" OR LOWER(tradeNames_string) LIKE "%benoxaprofen%" OR LOWER(drugSynonyms_string) LIKE "%benoxaprofen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5509', 'drugName': 'Benoxaprofen', 'tradeNames_string': 'Oraflex', 'drugSynonyms_string': 'Benoxaprofen, COMPD 90459, COMPOUND 90459, Coxigon, NSC-299582, Opren', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ALOX12 (ENSG00000108839)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.543 | Q17 | What gene does the drug Metaproterenol Sulfate target? | The drug Metaproterenol Sulfate targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metaproterenol sulfate%" OR LOWER(tradeNames_string) LIKE "%metaproterenol sulfate%" OR LOWER(drugSynonyms_string) LIKE "%metaproterenol sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5266', 'drugName': 'Metaproterenol Sulfate', 'tradeNames_string': 'Alupent, Alupent obstetric, Metaproterenol sulfate, Prometa', 'drugSynonyms_string': 'Metaproterenol sulfate, Metaproterenol sulphate, Orciprenaline sulfate, Orciprenaline sulphate, TH-152', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Drug Dependence (EFO_0003890)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.765 | Q17 | What gene does the drug Ci-988 target? | The drug Ci-988 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCKBR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ci-988%" OR LOWER(tradeNames_string) LIKE "%ci-988%" OR LOWER(drugSynonyms_string) LIKE "%ci-988%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6149', 'drugName': 'Ci-988', 'tradeNames_string': '', 'drugSynonyms_string': 'Ci-988, PD-134308', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCKBR (ENSG00000110148)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1905 | Q17 | What gene does the drug Ave-1642 target? | The drug Ave-1642 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IGF1R. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ave-1642%" OR LOWER(tradeNames_string) LIKE "%ave-1642%" OR LOWER(drugSynonyms_string) LIKE "%ave-1642%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5824', 'drugName': 'Ave-1642', 'tradeNames_string': '', 'drugSynonyms_string': 'AVE-1642, AVE1642, Ave 1642, Ave-1642', 'linkedDiseasesDrug_string': 'Breast Neoplasm (EFO_0003869), Multiple Myeloma (EFO_0001378), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IGF1R (ENSG00000140443)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1071 | Q17 | What gene does the drug Dimethyl Fumarate target? | The drug Dimethyl Fumarate targets the gene KEAP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dimethyl fumarate%" OR LOWER(tradeNames_string) LIKE "%dimethyl fumarate%" OR LOWER(drugSynonyms_string) LIKE "%dimethyl fumarate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3182', 'drugName': 'Dimethyl Fumarate', 'tradeNames_string': 'Tecfidera', 'drugSynonyms_string': 'AZL 0 211089, AZL O 211089, AZL-0211089, AZL-O-211089, BG 00012, BG 12, BG-00012, BG-12, BG00012, Dimethyl fumar, Dimethyl fumarate, FAG-201, FP-187, FP187, Fumaric acid dimethyl ester, LAS-41008, LAS41008, Las41008, NSC-167432, NSC-25942, Panaclar', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Gliosarcoma (EFO_1001465), Intracerebral Hemorrhage (EFO_0005669), Chronic Lymphocytic Leukemia (EFO_0000095), Ischemic Stroke (HP_0002140), Multiple Sclerosis (MONDO_0005301), Chronic Progressive Multiple Sclerosis (EFO_0003840), Psoriatic Arthritis (EFO_0003778), Severe Acute Respiratory Syndrome (EFO_0000694), Rheumatoid Arthritis (EFO_0000685), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Obstructive Sleep Apnea (EFO_0003918), Cutaneous T-Cell Lymphoma (EFO_0002913), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1209 | Q17 | What gene does the drug Acetohexamide target? | The drug Acetohexamide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acetohexamide%" OR LOWER(tradeNames_string) LIKE "%acetohexamide%" OR LOWER(drugSynonyms_string) LIKE "%acetohexamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1234', 'drugName': 'Acetohexamide', 'tradeNames_string': 'Acetohexamide, Dimelor, Dymelor', 'drugSynonyms_string': '33006, Acetohexamide, NSC-759128', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Diabetes Mellitus (EFO_0000400)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.248 | Q17 | What gene does the drug Biib-015 target? | The drug Biib-015 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CRIPTO. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%biib-015%" OR LOWER(tradeNames_string) LIKE "%biib-015%" OR LOWER(drugSynonyms_string) LIKE "%biib-015%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5970', 'drugName': 'Biib-015', 'tradeNames_string': '', 'drugSynonyms_string': 'BIIB-015, Biib-015', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CRIPTO (ENSG00000241186)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1431 | Q17 | What gene does the drug Insulin Zinc Susp Prompt Beef target? | The drug Insulin Zinc Susp Prompt Beef targets the gene INSR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%insulin zinc susp prompt beef%" OR LOWER(tradeNames_string) LIKE "%insulin zinc susp prompt beef%" OR LOWER(drugSynonyms_string) LIKE "%insulin zinc susp prompt beef%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3871', 'drugName': 'Insulin Zinc Susp Prompt Beef', 'tradeNames_string': 'Semilente insulin', 'drugSynonyms_string': 'Insulin zinc susp prompt beef', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'INSR (ENSG00000171105)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1137 | Q17 | What gene does the drug Laropiprant target? | The drug Laropiprant targets the gene PTGDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%laropiprant%" OR LOWER(tradeNames_string) LIKE "%laropiprant%" OR LOWER(drugSynonyms_string) LIKE "%laropiprant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1831', 'drugName': 'Laropiprant', 'tradeNames_string': '', 'drugSynonyms_string': 'Cordaptive, Laropiprant, MK-0524', 'linkedDiseasesDrug_string': 'Hyperlipidemia (MONDO_0021187), Flushing (HP_0031284), Rosacea (EFO_1000760), Familial Hypercholesterolemia (EFO_0004911), Combined Hyperlipidemia (Orphanet_79211), Hypercholesterolemia (HP_0003124), Disorder Of Lipid Metabolism (Orphanet_309005), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGDR (ENSG00000168229)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.791 | Q17 | What gene does the drug Diphenidol target? | The drug Diphenidol targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%diphenidol%" OR LOWER(tradeNames_string) LIKE "%diphenidol%" OR LOWER(drugSynonyms_string) LIKE "%diphenidol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1476', 'drugName': 'Diphenidol Hydrochloride', 'tradeNames_string': 'Vontrol', 'drugSynonyms_string': 'Cephadol, Diphenidol hcl, Diphenidol hydrochloride, NSC-23012, SK&F 478-A, SK-478-A', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4667', 'drugName': 'Diphenidol', 'tradeNames_string': 'Vontrol', 'drugSynonyms_string': 'Difenidol, Difenidol hydrochloride, Diphenidol, SK&F 478, SK&F-478, SK-478, Vontrol', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1744 | Q17 | What gene does the drug Flysyn target? | The drug Flysyn is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FLT3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flysyn%" OR LOWER(tradeNames_string) LIKE "%flysyn%" OR LOWER(drugSynonyms_string) LIKE "%flysyn%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_136', 'drugName': 'Flysyn', 'tradeNames_string': '', 'drugSynonyms_string': 'FLYSYN, Flysyn', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'FLT3 (ENSG00000122025)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.495 | Q17 | What gene does the drug Bezafibrate target? | The drug Bezafibrate targets 3 genes: PPARG, PPARD and PPARA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bezafibrate%" OR LOWER(tradeNames_string) LIKE "%bezafibrate%" OR LOWER(drugSynonyms_string) LIKE "%bezafibrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1564', 'drugName': 'Bezafibrate', 'tradeNames_string': 'Bezagen xl, Bezalip, Bezalip-mono, Fibrazate xl, Liparol xl, Zimbacol xl', 'drugSynonyms_string': 'BM 15.075, BM-15.075, BM-15075, Bezafibrate, Bezatol sr, NSC-758174', 'linkedDiseasesDrug_string': 'Combined Hyperlipidemia (Orphanet_79211), Cardiovascular Disease (EFO_0000319), Mitochondrial Disease (MONDO_0044970), Bipolar Disorder (MONDO_0004985), Myelodysplastic Syndrome (EFO_0000198), Type 2 Diabetes Mellitus (MONDO_0005148), Sclerosing Cholangitis (EFO_0004268), Primary Biliary Cirrhosis (EFO_1001486)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPARG (ENSG00000132170), PPARA (ENSG00000186951), PPARD (ENSG00000112033)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.157 | Q17 | What gene does the drug Lansoprazole target? | The drug Lansoprazole targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lansoprazole%" OR LOWER(tradeNames_string) LIKE "%lansoprazole%" OR LOWER(drugSynonyms_string) LIKE "%lansoprazole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2720', 'drugName': 'Lansoprazole', 'tradeNames_string': 'Lansoprazole, Opiren, Prevacid, Prevacid 24 hr, Prevacid Delayed Release, Prevacid Solutab, Prevacid iv, Zoton', 'drugSynonyms_string': 'A-65006, AG-1749, Agopton, Lansoprazole, Lansox, Lanzoprazole, Lanzor, Limpidex, NSC-758638, Ogast, Ogastoro, Prevonco, Takepron', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Pseudomyxoma Peritonei (EFO_0007456), Pain (EFO_0003843), Idiopathic Pulmonary Fibrosis (EFO_0000768), Endometrial Cancer (MONDO_0011962), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Laryngopharyngeal Reflux (EFO_1001355), Peptic Ulcer (HP_0004398), Gastritis (EFO_0000217), Premature Birth (EFO_0003917), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Gastroesophageal Reflux Disease (EFO_0003948), Cervical Cancer (MONDO_0002974), Gout (EFO_0004274), Rectum Cancer (EFO_1000657), Osteoarthritis (MONDO_0005178), Neoplasm (EFO_0000616), Eosinophilic Esophagitis (EFO_0004232), Cystic Fibrosis (MONDO_0009061), Type 1 Diabetes Mellitus (MONDO_0005147), Helicobacter Pylori Infectious Disease (EFO_1000961)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_908', 'drugName': 'Dexlansoprazole', 'tradeNames_string': 'Dexilant, Dexilant solutab, Kapidex', 'drugSynonyms_string': '(r)-lansoprazole, Dexlansoprazole, Kapidex, Lansoprazole r-form, Lansoprazole, (r)-, NSC-758710, T-168390, TAK-390', 'linkedDiseasesDrug_string': "Esophagitis (HP_0100633), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Peptic Ulcer (HP_0004398), Barrett'S Esophagus (EFO_0000280), Gastroesophageal Reflux Disease (EFO_0003948)", 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.970 | Q17 | What gene does the drug Cabergoline target? | The drug Cabergoline targets the gene DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cabergoline%" OR LOWER(tradeNames_string) LIKE "%cabergoline%" OR LOWER(drugSynonyms_string) LIKE "%cabergoline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4668', 'drugName': 'Cabergoline', 'tradeNames_string': 'Cabaser, Cabergoline, Dostinex', 'drugSynonyms_string': 'Cabergoline, FCE 21336, FCE-21336, Velactis', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Hypothalamic Neoplasm (EFO_1000979), Breast Cancer (MONDO_0007254), Substance Abuse (MONDO_0002491), Infertility (EFO_0000545), Obesity (EFO_0001073), Parkinson Disease (MONDO_0005180), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Cocaine Dependence (EFO_0002610), Endometriosis (EFO_0001065), Reproductive System Disease (EFO_0000512), Restless Legs Syndrome (EFO_0004270)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.860 | Q17 | What gene does the drug Lecozotan target? | The drug Lecozotan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lecozotan%" OR LOWER(tradeNames_string) LIKE "%lecozotan%" OR LOWER(drugSynonyms_string) LIKE "%lecozotan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1643', 'drugName': 'Lecozotan', 'tradeNames_string': '', 'drugSynonyms_string': 'Lecozotan', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6152', 'drugName': 'Lecozotan Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Lecozotan hcl, Lecozotan hydrochloride, SRA-333', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1325 | Q17 | What gene does the drug Metharbital target? | The drug Metharbital targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metharbital%" OR LOWER(tradeNames_string) LIKE "%metharbital%" OR LOWER(drugSynonyms_string) LIKE "%metharbital%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_341', 'drugName': 'Metharbital', 'tradeNames_string': 'Gemonil', 'drugSynonyms_string': 'Endiemal, Metharbital, Metharbital ciii, Metharbitone, NSC-27156', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.632 | Q17 | What gene does the drug Amibegron Hydrochloride target? | The drug Amibegron Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ADRB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amibegron hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amibegron hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amibegron hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1749', 'drugName': 'Amibegron Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Amibegron hcl, Amibegron hydrochloride, SR-58611A, SR58611A, Sr-58611a', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.692 | Q17 | What gene does the drug Apazone target? | The drug Apazone targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%apazone%" OR LOWER(tradeNames_string) LIKE "%apazone%" OR LOWER(drugSynonyms_string) LIKE "%apazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3917', 'drugName': 'Apazone', 'tradeNames_string': 'Rheumox, Rheumox 600', 'drugSynonyms_string': 'AHR-3018, Apazone, Apazone dihydrate, Azapropazone, Azapropazone dihydrate, Cinnopropazone, MI-85, MI-85DI, NSC-102824, Prolixan', 'linkedDiseasesDrug_string': 'Rheumatic Disease (EFO_0005755)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1562 | Q17 | What gene does the drug Glyburide target? | The drug Glyburide targets 2 genes: KCNJ11 and ABCC8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glyburide%" OR LOWER(tradeNames_string) LIKE "%glyburide%" OR LOWER(drugSynonyms_string) LIKE "%glyburide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_934', 'drugName': 'Glyburide', 'tradeNames_string': 'Calabren, Daonil, Diabeta, Diabetamide 2.5, Diabetamide 5, Euglucon, Gliken, Glyburide, Glyburide (micronized), Glynase, Glynase Prestab, Lederglib, Libanil, Malix, Micronase, Semi-daonil', 'drugSynonyms_string': 'Cirara, Glibenclamide, Glibenclamidum, Glybenclamide, Glyburide, HB 419, HB-419, NSC-759618, U-26,45, U-26,452, U-26452', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Ischemic Stroke (HP_0002140), Angina Pectoris (EFO_0003913), Stroke (EFO_0000712), Gestational Diabetes (EFO_0004593), Brain Injury (MONDO_0043510), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Spinal Cord Injury (EFO_1001919)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNJ11 (ENSG00000187486), ABCC8 (ENSG00000006071)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.575 | Q17 | What gene does the drug Ritonavir target? | The drug Ritonavir targets 4 genes: CYP3A43, CYP3A5, CYP3A4 and CYP3A7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ritonavir%" OR LOWER(tradeNames_string) LIKE "%ritonavir%" OR LOWER(drugSynonyms_string) LIKE "%ritonavir%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2751', 'drugName': 'Ritonavir', 'tradeNames_string': 'Norvir, Ritonavir', 'drugSynonyms_string': 'A-84538, ABBOTT-84538, ABT-538, Empetus, NSC-693184, Norvir, Ritomune, Ritonavir, Ritonavir related compounds mixture, Ritonavirum, Ritovir, Viekirax, Viriton', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Infection (EFO_0000544), Pneumonia (EFO_0003106), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), Aids (EFO_0000765), Anal Neoplasm (EFO_0003835), Pregnancy (EFO_0002950), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Hepatitis C Virus Infection (EFO_0003047), Hepatitis B Virus Infection (EFO_0004197), Hypertension (EFO_0000537), Hepatitis D Virus Infection (EFO_0007304), Middle East Respiratory Syndrome (MONDO_0100116), Acute Respiratory Distress Syndrome (EFO_1000637), Metastasis (EFO_0009708), Insulin Resistance (EFO_0002614), Viral Disease (EFO_0000763), Hiv-1 Infection (EFO_0000180), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Mycobacterium Avium Complex Disease (EFO_0007386), Hiv Infection (EFO_0000764), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kaposi'S Sarcoma (EFO_0000558), Sarcoma (EFO_0000691), Kidney Disease (EFO_0003086), Tuberculosis (MONDO_0018076), Glioblastoma Multiforme (EFO_0000519), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2752', 'drugName': 'Ritonavir', 'tradeNames_string': 'Norvir, Ritonavir', 'drugSynonyms_string': 'A-84538, ABBOTT-84538, ABT-538, Empetus, NSC-693184, Norvir, Ritomune, Ritonavir, Ritonavir related compounds mixture, Ritonavirum, Ritovir, Viekirax, Viriton', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Infection (EFO_0000544), Pneumonia (EFO_0003106), Liver Disease (EFO_0001421), Covid-19 (MONDO_0100096), Pulmonary Arterial Hypertension (EFO_0001361), Aids (EFO_0000765), Anal Neoplasm (EFO_0003835), Pregnancy (EFO_0002950), Coronavirus Infectious Disease (EFO_0007224), Malaria (EFO_0001068), Hepatitis C Virus Infection (EFO_0003047), Hepatitis B Virus Infection (EFO_0004197), Hypertension (EFO_0000537), Hepatitis D Virus Infection (EFO_0007304), Middle East Respiratory Syndrome (MONDO_0100116), Acute Respiratory Distress Syndrome (EFO_1000637), Metastasis (EFO_0009708), Insulin Resistance (EFO_0002614), Viral Disease (EFO_0000763), Hiv-1 Infection (EFO_0000180), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Mycobacterium Avium Complex Disease (EFO_0007386), Hiv Infection (EFO_0000764), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kaposi'S Sarcoma (EFO_0000558), Sarcoma (EFO_0000691), Kidney Disease (EFO_0003086), Tuberculosis (MONDO_0018076), Glioblastoma Multiforme (EFO_0000519), Severe Acute Respiratory Syndrome (EFO_0000694)", 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1909 | Q17 | What gene does the drug Ofatumumab target? | The drug Ofatumumab targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ofatumumab%" OR LOWER(tradeNames_string) LIKE "%ofatumumab%" OR LOWER(drugSynonyms_string) LIKE "%ofatumumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3424', 'drugName': 'Ofatumumab', 'tradeNames_string': 'Arzerra', 'drugSynonyms_string': '2F2, GSK-1841157, GSK1841157, HUMAX-CD20, HUMAX-CD20 2F2, HUMAX-CD20, 2F2, HUMAX-CD20-2F2, Ofatumumab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Aids (EFO_0000765), Burkitts Lymphoma (EFO_0000309), Nephrotic Syndrome (EFO_0004255), Mantle Cell Lymphoma (EFO_1001469), Pemphigus Vulgaris (EFO_0004719), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Diffuse Large B-Cell Lymphoma (EFO_0000403), Immune System Disease (EFO_0000540), Lymphoblastic Lymphoma (MONDO_0000873), Waldenstrom Macroglobulinemia (EFO_0009441), Rheumatoid Arthritis (EFO_0000685), Hodgkins Lymphoma (EFO_0000183), Lymphoid Leukemia (EFO_0004289), Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Pemphigus (EFO_1000749), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Melanoma (EFO_0000756)', 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.